Moderna and Merck's personalized skin cancer vaccine cleared its first large-scale trial
The mRNA-based vaccine combined with Keytruda reduced melanoma recurrence in more than 1,100 patients whose cancer had been surgically removed
We haven't written up this one. Quartz has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.
- STAT+: Moderna and Merck say mRNA cancer vaccine succeeded in late-stage melanoma trial statnews.com
- Merck, Moderna declare Phase 3 success for personalized mRNA cancer vaccine endpoints.news
- Personalized cancer vaccine from Moderna, Merck shows promise in first late-stage melanoma trial cnbc.com
- Moderna share price doubles on melanoma vaccine trial success ft.com
